Former president Donald Trump may not seek to dismantle CMS’ drug pricing negotiation program if elected to another term, according to former HHS Secretary Alex Azar, who said Trump could instead seek to please economic populists in the Republican Party by building on the program and out-negotiate the Biden administration by seeking to get even lower drug prices. Azar, who led HHS from 2018 to 2021, said at a webinar hosted by Avalere Wednesday (Aug. 14) he expects to see...